Testing a copper-based scan and treatment in advanced cancers
Part of Cancer, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed metastatic solid tumor; or specifically kidney cancer, bladder (urothelial) cancer, or prostate cancer (with criteria met)
- You must be 18 or older and able to give informed consent
- Your body’s organ blood-test numbers must be adequate (kidney, liver/bilirubin, and blood counts)
- Your energy level score (ECOG) must be 0 or 1
- For kidney/bladder and prostate groups: you plan to receive an immune checkpoint inhibitor
- For kidney/bladder and prostate groups: you can safely get paired tumor biopsies (small tissue samples) from accessible lesions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new imaging drug that may help your doctor see the exact location of prostate cancer using a PET scan. The imaging is done before surgery to remove the prostate or, if you have recurrence, to find where the cancer has returned.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.